Merck partners with King’s College London to develop painkillers
11-03-2019
Biotech firm to use Merck’s CRISPR patents in rodent models
13-12-2018
Artur / iStockphoto.com
German pharmaceutical company Merck Group has granted US biotech firm Vertex a licence to two DNA-dependent protein kinases (DNA-PK) inhibitors.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Merck Group, Vertex, CRISPR/Cas9, DNA-PK, Belén Garijo, patent licensing, gene editing, oncology
